Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xylitol and L-carnitine PD Solutions in ESRD
NCT00858182Phase 2Withdrawn
- Sponsor
- Iperboreal Pharma
- Start
- May 2009
- Primary completion
- Oct 2012
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label trial of xylitol and levocarnitine in end stage renal disease (ESRD) (2 arms), sponsored by Iperboreal Pharma. Primary endpoint: Ultrafiltration efficacy of PD solutions containing L-Carnitine and Xylitol at 4 weeks. Planned start May 2009; status: withdrawn.
02
Drugs
xylitollevocarnitine
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT00858182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00858182.